

Francesc Fernandez-Avils

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4183291/publications.pdf>

Version: 2024-02-01

39
papers

578
citations

687363

13
h-index

642732

23
g-index

40
all docs

40
docs citations

40
times ranked

1051
citing authors

#	ARTICLE	IF	CITATIONS
1	Case-Control Comparison of At-Home to Total Hospital Care for Autologous Stem-Cell Transplantation for Hematologic Malignancies. <i>Journal of Clinical Oncology</i> , 2006, 24, 4855-4861.	1.6	63
2	Improving safety of autologous haematopoietic stem cell transplantation in patients with Crohn's disease. <i>Gut</i> , 2016, 65, 1456-1462.	12.1	56
3	Autologous Haematopoietic Stem Cell Transplantation for Refractory Crohn's Disease: Efficacy in a Single-Centre Cohort. <i>Journal of Crohn's and Colitis</i> , 2017, 11, 1161-1168.	1.3	56
4	Single Antigen-Mismatched Unrelated Hematopoietic Stem Cell Transplantation Using High-Dose Post-Transplantation Cyclophosphamide Is a Suitable Alternative for Patients Lacking HLA-Matched Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1196-1202.	2.0	50
5	Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation Score Allows a Better Stratification of High-Risk Patients Undergoing Reduced-Toxicity Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 66-72.	2.0	41
6	Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2556-2562.	3.0	39
7	Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1825-1831.	2.0	34
8	Changing epidemiology of bloodstream infection in a 25-years hematopoietic stem cell transplant program: current challenges and pitfalls on empiric antibiotic treatment impacting outcomes. <i>Bone Marrow Transplantation</i> , 2020, 55, 603-612.	2.4	33
9	Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis. <i>Bone Marrow Transplantation</i> , 2020, 55, 1264-1271.	2.4	21
10	Innovative strategies minimize engraftment syndrome in multiple myeloma patients with novel induction therapy following autologous hematopoietic stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2018, 53, 1541-1547.	2.4	20
11	A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe. <i>Bone Marrow Transplantation</i> , 2020, 55, 965-973.	2.4	15
12	High-Dose Cyclophosphamide and Tacrolimus as Graft-versus-Host Disease Prophylaxis for Matched and Mismatched Unrelated Donor Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 619.e1-619.e8.	1.2	15
13	Quantitative PCR Is Faster, More Objective, and More Reliable Than Immunohistochemistry for the Diagnosis of Cytomegalovirus Gastrointestinal Disease in Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2281-2286.	2.0	14
14	Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1703-1712.	2.0	13
15	Deleterious Effect of Steroids on Cytomegalovirus Infection Rate after Allogeneic Stem Cell Transplantation Depends on Pretransplant Cytomegalovirus Serostatus of Donors and Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2088-2093.	2.0	11
16	Prolonged viral replication in patients with hematologic malignancies hospitalized with COVID-19. <i>Haematologica</i> , 2022, 107, 1731-1735.	3.5	11
17	Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs. <i>PLoS ONE</i> , 2021, 16, e0254135.	2.5	10
18	The induction strategies administered in the treatment of multiple myeloma exhibit a deleterious effect on the endothelium. <i>Bone Marrow Transplantation</i> , 2020, 55, 2270-2278.	2.4	9

#	ARTICLE	IF	CITATIONS
19	Risk Factors for Mortality in Hematopoietic Stem Cell Transplantation Recipients with Bloodstream Infection: Points To Be Addressed by Future Guidelines. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 501.e1-501.e6.	1.2	9
20	Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 1565-1574.	1.3	8
21	PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 489.e1-489.e9.	1.2	7
22	Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. <i>Bone Marrow Transplantation</i> , 2019, 54, 1295-1303.	2.4	6
23	Low-dose total-body irradiation and fludarabine followed by hematopoietic cell transplantation from HLA-identical sibling donors do not induce complete T-cell donor engraftment in most patients with progressive hematologic diseases. <i>Experimental Hematology</i> , 2003, 31, 934-940.	0.4	5
24	Impact of transplant eligibility and availability of a human leukocyte antigen-identical matched related donor on outcome of older patients with acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2015, 56, 2812-2818.	1.3	5
25	The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. <i>PLoS ONE</i> , 2020, 15, e0241778.	2.5	5
26	Genetic Polymorphisms in the Inflammasomes Are Associated with Relapse and Survival in HLA-Identical Sibling Donor Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2007, 110, 1075-1075.	1.4	5
27	Pharmacodynamics of T cell function for monitoring pharmacologic immunosuppression after allogeneic hematopoietic stem cell transplantation. <i>International Journal of Hematology</i> , 2017, 105, 497-505.	1.6	4
28	At-Home Management of Adult Patients Following Consolidation Chemotherapy for Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 3692-3692.	1.4	4
29	Romiplostim for the treatment of glioblastoma-related paraneoplastic autoimmune thrombocytopenia refractory to conventional therapy. <i>Annals of Hematology</i> , 2016, 95, 665-666.	1.8	2
30	Personalized at-home autologous hematopoietic stem cell transplantation during the SARS-CoV-2 outbreak. <i>Leukemia Research</i> , 2021, 106, 106589.	0.8	2
31	Donor's Mannan-Binding Lectin (MBL) Gene Polymorphism Is Associated with Invasive Fungal Infection Following Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2004, 104, 2220-2220.	1.4	2
32	Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of a Multicenter Study from the Grupo Español De Trasplante Hematopoyético (GETH). <i>Blood</i> , 2018, 132, 200-200.	1.4	1
33	Response to Proteasome Inhibitors and Immunomodulatory Drugs before and after Allogeneic Transplantation in Patients with Multiple Myeloma: A Long Term Follow up Study. <i>Blood</i> , 2016, 128, 3436-3436.	1.4	1
34	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. <i>Bone Marrow Transplantation</i> , 0, , .	2.4	1
35	Impact of Dendritic Cell CD16+ Recovery on Outcome after Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 1409-1409.	1.4	0
36	Polymorphisms of NOD2/CARD15 Are Associated with Clinical Outcome in T-Cell Depleted HLA-Identical Sibling Allogeneic Stem Cell Transplantation.. <i>Blood</i> , 2005, 106, 1408-1408.	1.4	0

#	ARTICLE	IF	CITATIONS
37	Endothelial Dysfunction in Autologous Hematopoietic Stem Cell Transplantation.. Blood, 2007, 110, 4855-4855.	1.4	0
38	Strategies for Graft Versus Host Disease Prophylaxis after Reduced-Intensity Conditioning Transplantation: Combination of Sirolimus Plus Tacrolimus Allows to Obtain the Best Outcome. Blood, 2014, 124, 1165-1165.	1.4	0
39	Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. Blood, 2021, 138, 3925-3925.	1.4	0